Citius Pharmaceuticals (CTXR) Other Non-Current Assets (2014 - 2026)

Citius Pharmaceuticals (CTXR) has reported Other Non-Current Assets for 13 consecutive years, with $98.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets fell 3.93% year-over-year to $98.2 million; the trailing twelve-month figure through Jun 2026 stood at $98.2 million (down 3.93% YoY), and the FY2025 full-year result was $102.2 million, changed 0.0% from the prior year.
• Other Non-Current Assets eased to $98.2 million in Q2 2026 per CTXR's latest filing, from $100.1 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $102.2 million in Q3 2024 and bottomed at $59.4 million in Q1 2024.
• Historically, Other Non-Current Assets has averaged $82.2 million across 5 years, with a median of $68.8 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 138.96% in 2022, then decreased 13.64% in 2024.
• Over 5 years, Other Non-Current Assets stood at $68.8 million in 2022, then changed by 0.0% to $68.8 million in 2023, then surged by 48.56% to $102.2 million in 2024, then decreased by 0.56% to $101.6 million in 2025, then decreased by 3.39% to $98.2 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $98.2 million, $100.1 million, and $101.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.